Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

• Sponsor: Massachusetts General Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT02560025
• Collaborator: Takeda (Industry)
• Enrollment: 42
• Locations: 2
• Arm: 1
• Duration (Months): 36
• Patients Per Site: 21
• Patients Per Site Per Month: 0.6

Study Details

Study Description

Brief Summary

This research study is studying a targeted therapy (a form of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells) as a possible treatment for high-risk acute myeloid leukemia.

The names of the study interventions involved in this study are:

• Alisertib / MLN8237

• Cytarabine / Cytosine Arabinoside

• Idarubicin / Idarubicin hydrochloride

• Daunorubicin (Can be used in place of idarubicin)

Condition or Disease	Intervention/Treatment	Phase
Acute Myeloid Leukemia	Drug: Alisertib; Drug: Cytarabine; Drug: Idarubicin; Drug: Daunorubicin	Phase 2

Detailed Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

As part of this research study, the participant will take alisertib in combination with conventional chemotherapies, idarubicin and cytarabine. Alisertib has not been approved by the FDA (U.S. Food and Drug Administration) for acute myeloid leukemia (AML). However, cytarabine and idarubicin have both been approved by the FDA for treatment of AML. It also means that the FDA (U.S. Food and Drug Administration) has not approved giving alisertib with idarubicin and cytarabine for use in participants, including participants with this type of cancer.

Earlier pre-clinical studies and clinical trials have suggested the alisertib may have clinical promise as a single agent in acute myeloid leukemia. Alisertib is a selective small molecule inhibitor of Aurora A kinase, an enzyme which may play a role in the survival of leukemia cells. Alisertib is being studied for the treatment of advanced malignancies, including AML. Essentially, this means that alisertib may work to halt the growth of malignancy (abnormal cells dividing without control and invading nearby tissues) through a targeted mechanism. By combining alisertib with standard chemotherapy, the hope is to enhance the efficacy of current treatment used for acute myeloid leukemia. An earlier study of this combination has completed accrual, and demonstrated that the regimen is well tolerated.

Through this study, the investigators would like to determine if the addition of alisertib to standard 7+3 chemotherapy improves efficacy as measured by the rate of complete remission (a decreased or disappearance of signs and symptoms of cancer).

Study Design

• Study Type: Interventional
• Actual Enrollment: 42 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia
• Study Start Date: Dec 1, 2015
• Actual Primary Completion Date: Oct 1, 2017
• Actual Study Completion Date: Dec 1, 2018

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Alisertib / MLN8237 Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with "5+2" chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles.

Drug: Alisertib; Other Names: MLN8237 ; Drug: Cytarabine; Other Names: Cytosine Arabinoside ; Drug: Idarubicin; Other Names: Idarubicin hydrochloride ; Drug: Daunorubicin; Can be used in place of idarubicin; Other Names: Cerubidine®

Outcome Measures

Primary Outcome Measures

1. Number of Participants That Achieved Complete Remission [From the start of treatment until the end of study treatment, up to approximately 10 months]

   The number of participants that achieved a best overall response of complete remission while on study. Complete remission (CR): Bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an ANC of at least 1000/μL and a platelet count of 100,000/μL, absence of blast in peripheral blood, absence of identifiable leukemic cells in the bone marrow, existing extramedullary disease. If possible, at least one bone marrow biopsy should be performed to confirm CR.

2. Number of Participants That Achieved Complete Remission With Incomplete Blood Count Recovery (CRi) [From the start of treatment until the end of study treatment, up to approximately 10 months]

   The number of participants that achieved a best overall response of CRi while on study. Complete Remission with Incomplete Blood Count Recovery (CRi): Same as for CR but without achievement of ANC at least 1000/uL (CRi) and/or platelet count of 100,000/uL (CRp).

Secondary Outcome Measures

1. 1 Year Overall Survival Rate [1 Year]

   The percentage of participants alive at one year

2. Median Relapse Free Survival [From the time of treatment response until death or disease progression (up to about one year)]

   The median amount of time from achieving a complete remission to the first of disease recurrence or death. RFS applies only to the subset of patients who achieve a CR+CRi at the end of induction therapy. Complete remission (CR): Bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an ANC of at least 1000/μL and a platelet count of 100,000/μL, absence of blast in peripheral blood, absence of identifiable leukemic cells in the bone marrow, existing extramedullary disease. If possible, at least one bone marrow biopsy should be performed to confirm CR. Complete remission with incomplete blood count recovery (CRi): Same as CR but without achievement of specified ANC and/or platelet count Recurrence/ morphologic relapse: reappearance of leukemic blasts in the peripheral blood or >5% blasts in the bone marrow not attributable to any other cause

3. Median Duration of Remission [From the time of first remission to disease progression or death, median duration of 12.8 months]

   The median amount of time from first achieving remission to disease progression (with patients censored at death). Complete remission (CR): Bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an ANC of at least 1000/μL and a platelet count of 100,000/μL, absence of blast in peripheral blood, absence of identifiable leukemic cells in the bone marrow, existing extramedullary disease. If possible, at least one bone marrow biopsy should be performed to confirm CR. Complete remission with incomplete blood count recovery (CRi): Same as CR but without achievement of specified ANC and/or platelet count Recurrence/ morphologic relapse: reappearance of leukemic blasts in the peripheral blood or >5% blasts in the bone marrow not attributable to any other cause

4. Number of Participants With Serious Adverse Events [From the start of treatment until 30 days after the last dose of a study drug is received, up to approximately 11 months]

   Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 4). Adverse events were considered to be Serious Adverse Events (SAE) if they were grade 3 or greater and deemed to be possibly, probably, or definitely related to the study treatment.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Participants must have pathologically confirmed, newly diagnosed high-risk acute myeloid leukemia, as defined by at least one of the following criteria

• Age greater than or equal to 65 years

• Poor risk karyotype, as per Leukemianet criteria

• Antecedent or underlying myelodysplastic syndrome or myeloproliferative neoplasm

• AML with MDS-related changes

• Adults, age 18 years or older at the time of diagnosis, eligible for standard induction chemotherapy according to their treating physician.

• ECOG performance status 0-2 (Karnofsky ≥60%, see Appendix A)

• Left ventricular ejection fraction > 50% as measured by echocardiogram or MUGA scan

• Must not have received systemic antineoplastic therapy including radiation therapy within 14 days of the study enrollment, except hydroxyurea or 6-mercaptopurine for the purposes of cytoreduction. Patients may also have received all-trans retinoic acid (ATRA) if there is an early suspicion of acute promyelocytic leukemia (APL, M3-AML), although if confirmed to have APL these patients will be excluded from the study.

• Adequate renal function as defined by: calculated creatinine clearance ≥40 mL/min (Cockcroft-Gualt Formula)

• Direct bilirubin < 2.0 x upper limit of normal (ULN), SGOT (AST) and SGPT (ALT)< 2.5 x ULN. AST and/or ALT may be up to 5X ULN if thought to be secondary to leukemia.

• The effects of alisertib on the developing human fetus are unknown. For this reason and because other chemotherapeutic agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and 6 months after completion of therapy.

• Subject must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after alisertib administration.

• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Patients will be excluded from this study if they do not otherwise fulfill criteria mentioned in bullet 3.1.1, and are found to harbor "intermediate" or "favorable" risk cytogenetics 41:

• In such patients, a sample to evaluate patient cytogenetics will be sent at the time of diagnosis per standard clinical care and the absence of favorable or intermediate-risk cytogenetics must be confirmed by Day 8. If the cytogenetic analysis reveals that the patient harbors non-poor risk cytogenetics, or if the cytogenetic results are not received prior to Day 8, the participant will be removed from the study.

• Patients with acute bilineal/biphenotypic leukemia

• Participants who have had chemotherapy or radiotherapy within 14 days prior to entering the study, except for hydroxyurea or 6-MP as noted.

• Participants who are receiving or have received any other investigational agents within 14 days of enrollment.

• Chemo-, hormono-, radio- or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug

• Persistence of clinically relevant therapy related toxicity from previous anti-cancer therapy

• Prior allogeneic bone marrow or organ transplantation

• Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.

• Current clinical central nervous system (CNS) symptoms deemed by the investigator to be related to leukemic CNS involvement (no lumbar puncture required, clinical assessment per investigator's judgment is sufficient).

• If applicable, patient with ≥Grade 2 peripheral neuropathy within 14 days before enrollment

• Prior treatment with alisertib

• Known history of hepatitis C infection or suspected currently active hepatitis C infection. Known or suspected history of hepatitis B infection will be excluded when any of the following conditions are met:

• Received hematopoietic stem cell transplantation (either allogenic or autologous), or

• Received any rituximab-containing treatment regimen in the last 12 months before entering the study, or

• Tested positive for the presence of at least 1 of the following 3 markers in blood (evaluated at screening): hepatitis B surface antigen (HBsAG), antibodies against hepatitis B core antigen (anti-HBc), or hepatitis B viral load (HBV DNA).

• Current or history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (LVEF <50%, as measured by MUGA scan or echocardiogram). Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant

• Known hypersensitivity to the trial drugs or other contraindication to standard "7+3" induction chemotherapy.

• Known history of uncontrolled sleep apnea syndrome, or sleep apnea requiring supplemental oxygen, and other conditions that could result in excessive daytime sleepiness.

• A medical condition requiring use of proton pump inhibitors (PPIs); or histamine 2 (H2) receptor antagonists. Patients who intermittently use these medications, must meet the following criteria:

• No use of PPIs within 5 days before the first dose of alisertib

• No use of H2 antagonist or pancreatic enzymes within 24 hours before the first dose of alisertib

• Patients with mental deficits or psychiatric conditions that preclude them from giving informed consent or following protocol.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Known GI disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib. Examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease.

• Pregnant women are excluded from this study because alisertib, along with standard induction chemotherapy, carries the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with alisertib as well as cytarabine and idarubicin, breastfeeding should be avoided. Confirmation that the subject is not pregnant must be established by a negative serum ß-human chorionic gonadotropin ( ß-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.

• Although not absolute exclusion criteria, because of known drug-drug interactions, below are issues that should be considered during enrollment:

• Treatment with clinically significant enzyme-inducing drugs, including known P-glycoprotein inducers (including St John's wort and rifampicin) should be used only if absolutely necessary and considered to be the best available choice for the patient. If possible, it is recommended that alternatives to known substrates, inhibitors or inducers of P-glycoprotein be considered. Cases should be discussed with the principal investigator, and may be allowed as per his/her discretion.

• Patients with psychological, familial, social, or geographic factors that otherwise preclude them from giving informed consent, following the protocol, or potentially hamper compliance with study treatment and follow-up.

• Patients who are otherwise felt unable to comply with the protocol, in the opinion of the investigator.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Massachusetts General Hospital	Boston	Massachusetts	United States	02114
2	Dana Farber Cancer Institute	Boston	Massachusetts	United States	02215

Sponsors and Collaborators

• Massachusetts General Hospital
• Takeda

Investigators

• Principal Investigator: Amir Fathi, MD, Massachusetts General Hospital

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - May 18, 2017

More Information

Publications

None provided.

• Responsible Party: Amir Fathi, Principal Investigator, Massachusetts General Hospital
• ClinicalTrials.gov Identifier: NCT02560025
• Other Study ID Numbers: 15-334
• First Posted: Sep 25, 2015
• Last Update Posted: May 5, 2020
• Last Verified: Apr 1, 2020

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Keywords provided by Amir Fathi, Principal Investigator, Massachusetts General Hospital: Acute Myeloid Leukemia
• Additional relevant MeSH terms: Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Cytarabine; Daunorubicin; Idarubicin

Study Results

Participant Flow

Arm/Group Title	Alisertib / MLN8237
Arm/Group Description	Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with "5+2" chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles.
Period Title: Overall Study
STARTED	42
COMPLETED	39
NOT COMPLETED	3

Baseline Characteristics

Arm/Group Title	Alisertib / MLN8237
Arm/Group Description	Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with "5+2" chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles.
Overall Participants	39
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	67
Sex: Female, Male (Count of Participants)
Female	14 35.9%
Male	25 64.1%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	0 0%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	0 0%
White	38 97.4%
More than one race	0 0%
Unknown or Not Reported	1 2.6%
Region of Enrollment (Count of Participants)
United States	39 100%
Cytogenetic Risk (Count of Participants)
High	13 33.3%
Intermediate	26 66.7%
Median White Blood Cell (WBC) Count (Thousand WBC/ microliter blood) [Median (Full Range) ]
Median (Full Range) [Thousand WBC/ microliter blood]	3.2

Outcome Measures

1. Primary Outcome

Title	Number of Participants That Achieved Complete Remission
Description	The number of participants that achieved a best overall response of complete remission while on study. Complete remission (CR): Bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an ANC of at least 1000/μL and a platelet count of 100,000/μL, absence of blast in peripheral blood, absence of identifiable leukemic cells in the bone marrow, existing extramedullary disease. If possible, at least one bone marrow biopsy should be performed to confirm CR.
Time Frame	From the start of treatment until the end of study treatment, up to approximately 10 months

Outcome Measure Data

Analysis Population Description

The three participants found to be ineligible after enrollment were excluded from the analysis

Arm/Group Title	Alisertib / MLN8237
Arm/Group Description	Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with "5+2" chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles.
Measure Participants	39
Count of Participants [Participants]	20 51.3%

2. Primary Outcome

Title	Number of Participants That Achieved Complete Remission With Incomplete Blood Count Recovery (CRi)
Description	The number of participants that achieved a best overall response of CRi while on study. Complete Remission with Incomplete Blood Count Recovery (CRi): Same as for CR but without achievement of ANC at least 1000/uL (CRi) and/or platelet count of 100,000/uL (CRp).
Time Frame	From the start of treatment until the end of study treatment, up to approximately 10 months

Outcome Measure Data

Analysis Population Description

The three participants found to be ineligible after enrollment were excluded from the analysis

Arm/Group Title	Alisertib / MLN8237
Arm/Group Description	Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with "5+2" chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles.
Measure Participants	39
Count of Participants [Participants]	5 12.8%

3. Secondary Outcome

Title	1 Year Overall Survival Rate
Description	The percentage of participants alive at one year
Time Frame	1 Year

Outcome Measure Data

Analysis Population Description

The three participants found to be ineligible after enrollment were excluded from the analysis

Arm/Group Title	Alisertib / MLN8237
Arm/Group Description	Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with "5+2" chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles.
Measure Participants	39
Number (95% Confidence Interval) [percentage of participants]	50 128.2%

4. Secondary Outcome

Title	Median Relapse Free Survival
Description	The median amount of time from achieving a complete remission to the first of disease recurrence or death. RFS applies only to the subset of patients who achieve a CR+CRi at the end of induction therapy. Complete remission (CR): Bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an ANC of at least 1000/μL and a platelet count of 100,000/μL, absence of blast in peripheral blood, absence of identifiable leukemic cells in the bone marrow, existing extramedullary disease. If possible, at least one bone marrow biopsy should be performed to confirm CR. Complete remission with incomplete blood count recovery (CRi): Same as CR but without achievement of specified ANC and/or platelet count Recurrence/ morphologic relapse: reappearance of leukemic blasts in the peripheral blood or >5% blasts in the bone marrow not attributable to any other cause
Time Frame	From the time of treatment response until death or disease progression (up to about one year)

Outcome Measure Data

Analysis Population Description

Participants that achieved a complete response

Arm/Group Title	Alisertib / MLN8237
Arm/Group Description	Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with "5+2" chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles.
Measure Participants	20
Median (95% Confidence Interval) [Months]	NA

5. Secondary Outcome

Title	Median Duration of Remission
Description	The median amount of time from first achieving remission to disease progression (with patients censored at death). Complete remission (CR): Bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an ANC of at least 1000/μL and a platelet count of 100,000/μL, absence of blast in peripheral blood, absence of identifiable leukemic cells in the bone marrow, existing extramedullary disease. If possible, at least one bone marrow biopsy should be performed to confirm CR. Complete remission with incomplete blood count recovery (CRi): Same as CR but without achievement of specified ANC and/or platelet count Recurrence/ morphologic relapse: reappearance of leukemic blasts in the peripheral blood or >5% blasts in the bone marrow not attributable to any other cause
Time Frame	From the time of first remission to disease progression or death, median duration of 12.8 months

Outcome Measure Data

Analysis Population Description

Participants that achieved a complete response

Arm/Group Title	Alisertib / MLN8237
Arm/Group Description	Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with "5+2" chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles.
Measure Participants	20
Median (Full Range) [Months]	12.8

6. Secondary Outcome

Title	Number of Participants With Serious Adverse Events
Description	Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 4). Adverse events were considered to be Serious Adverse Events (SAE) if they were grade 3 or greater and deemed to be possibly, probably, or definitely related to the study treatment.
Time Frame	From the start of treatment until 30 days after the last dose of a study drug is received, up to approximately 11 months

Outcome Measure Data

Analysis Population Description

The three participants found to be ineligible after enrollment were excluded from the analysis

Arm/Group Title	Alisertib / MLN8237
Arm/Group Description	Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with "5+2" chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles.
Measure Participants	39
Count of Participants [Participants]	27 69.2%

Adverse Events

Time Frame	From the start of treatment until 30 days after the last dose of a study drug is received, up to approximately 11 months
Adverse Event Reporting Description	The adverse events reported in the serious adverse event section represent CTCAE 4 grade 3 or greater adverse events that were deemed to be possibly, probably, or definitely related to study treatment.
Arm/Group Title	Alisertib / MLN8237
Arm/Group Description	Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with "5+2" chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles.
All Cause Mortality
	Alisertib / MLN8237
	Affected / at Risk (%)	# Events
Total	20/39 (51.3%)
Serious Adverse Events
	Alisertib / MLN8237
	Affected / at Risk (%)	# Events
Total	27/39 (69.2%)
Blood and lymphatic system disorders
Anemia	11/39 (28.2%)	11
Febrile neutropenia	16/39 (41%)	19
Gastrointestinal disorders
Colitis	1/39 (2.6%)	1
Diarrhea	2/39 (5.1%)	2
Dysphagia	1/39 (2.6%)	1
Esophagitis	2/39 (5.1%)	2
Mucositis oral	4/39 (10.3%)	4
Nausea	3/39 (7.7%)	3
Investigations
Alanine aminotransferase increased	3/39 (7.7%)	4
Aspartate aminotransferase increased	2/39 (5.1%)	3
Blood bilirubin increased	3/39 (7.7%)	4
Neutrophil count decreased	12/39 (30.8%)	14
Platelet count decreased	12/39 (30.8%)	17
Metabolism and nutrition disorders
Anorexia	9/39 (23.1%)	9
Hypophosphatemia	1/39 (2.6%)	1
Respiratory, thoracic and mediastinal disorders
Laryngeal mucositis	1/39 (2.6%)	1
Other (Not Including Serious) Adverse Events
	Alisertib / MLN8237
	Affected / at Risk (%)	# Events
Total	39/39 (100%)
Blood and lymphatic system disorders
Anemia	13/39 (33.3%)	25
Febrile neutropenia	15/39 (38.5%)	20
Cardiac disorders
Atrial fibrillation	4/39 (10.3%)	4
Cardiac arrest	3/39 (7.7%)	3
Pericardial effusion	4/39 (10.3%)	5
Sinus bradycardia	4/39 (10.3%)	4
Sinus tachycardia	2/39 (5.1%)	2
Ventricular arrhythmia	2/39 (5.1%)	2
Ventricular tachycardia	3/39 (7.7%)	3
Eye disorders
Blurred vision	2/39 (5.1%)	2
Floaters	2/39 (5.1%)	2
Gastrointestinal disorders
Abdominal distension	4/39 (10.3%)	4
Abdominal pain	8/39 (20.5%)	10
Anal fistula	2/39 (5.1%)	2
Colitis	5/39 (12.8%)	5
Constipation	7/39 (17.9%)	7
Diarrhea	29/39 (74.4%)	35
Dry mouth	3/39 (7.7%)	4
Dyspepsia	3/39 (7.7%)	3
Enterocolitis	3/39 (7.7%)	3
Esophagitis	3/39 (7.7%)	3
Gastroesophageal reflux disease	4/39 (10.3%)	4
Gastrointestinal disorders - Other, Lack of Appetite	2/39 (5.1%)	2
Mucositis oral	15/39 (38.5%)	17
Nausea	21/39 (53.8%)	27
Oral pain	3/39 (7.7%)	3
Vomiting	7/39 (17.9%)	9
General disorders
Chills	7/39 (17.9%)	7
Edema limbs	7/39 (17.9%)	7
Fatigue	22/39 (56.4%)	24
Fever	11/39 (28.2%)	14
Localized edema	2/39 (5.1%)	2
Non-cardiac chest pain	2/39 (5.1%)	2
Pain	3/39 (7.7%)	6
Infections and infestations
Catheter related infection	2/39 (5.1%)	2
Lung infection	10/39 (25.6%)	10
Sepsis	6/39 (15.4%)	7
Injury, poisoning and procedural complications
Fall	2/39 (5.1%)	2
Investigations
Alanine aminotransferase increased	12/39 (30.8%)	14
Alkaline phosphatase increased	15/39 (38.5%)	20
Aspartate aminotransferase increased	10/39 (25.6%)	13
Blood bilirubin increased	13/39 (33.3%)	18
Creatinine increased	2/39 (5.1%)	3
Neutrophil count decreased	9/39 (23.1%)	15
Platelet count decreased	11/39 (28.2%)	31
White blood cell decreased	2/39 (5.1%)	4
Metabolism and nutrition disorders
Anorexia	23/39 (59%)	28
Dehydration	2/39 (5.1%)	2
Hyperglycemia	3/39 (7.7%)	4
Hypernatremia	4/39 (10.3%)	5
Hyperuricemia	2/39 (5.1%)	2
Hypokalemia	3/39 (7.7%)	4
Hyponatremia	3/39 (7.7%)	3
Hypophosphatemia	4/39 (10.3%)	6
Musculoskeletal and connective tissue disorders
Generalized muscle weakness	2/39 (5.1%)	2
Pain in extremity	2/39 (5.1%)	2
Nervous system disorders
Dizziness	6/39 (15.4%)	7
Dysgeusia	4/39 (10.3%)	4
Headache	8/39 (20.5%)	10
Peripheral sensory neuropathy	2/39 (5.1%)	3
Sinus pain	2/39 (5.1%)	2
Somnolence	2/39 (5.1%)	3
Syncope	2/39 (5.1%)	2
Psychiatric disorders
Anxiety	5/39 (12.8%)	5
Confusion	6/39 (15.4%)	6
Delirium	3/39 (7.7%)	3
Depression	2/39 (5.1%)	2
Insomnia	9/39 (23.1%)	9
Renal and urinary disorders
Acute kidney injury	5/39 (12.8%)	8
Urinary urgency	2/39 (5.1%)	2
Respiratory, thoracic and mediastinal disorders
Cough	8/39 (20.5%)	8
Dyspnea	10/39 (25.6%)	11
Epistaxis	5/39 (12.8%)	5
Hypoxia	9/39 (23.1%)	10
Pleural effusion	6/39 (15.4%)	6
Pulmonary edema	5/39 (12.8%)	6
Respiratory failure	3/39 (7.7%)	4
Sore throat	4/39 (10.3%)	4
Skin and subcutaneous tissue disorders
Pruritus	3/39 (7.7%)	4
Rash maculo-papular	15/39 (38.5%)	18
Vascular disorders
Hematoma	2/39 (5.1%)	2
Hypertension	3/39 (7.7%)	3
Hypotension	6/39 (15.4%)	6
Thromboembolic event	4/39 (10.3%)	4

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.